Pruritus Therapeutic Global Market Report 2023
Major players in the pruritus therapeutic market are Allergan PLC, Astellas Pharma Inc., Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Galderm, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc.
New York, June 09, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pruritus Therapeutic Global Market Report 2023" - https://www.reportlinker.com/p06466449/?utm_source=GNW
, Sanofi, Abbott Laboratories, Almirall SA, Eisai Co Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., and Lupin.
The global pruritus therapeutic market is expected to grow from $12.09 billion in 2022 to $13.10 billion in 2023 at a compound annual growth rate (CAGR) of 8.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pruritus therapeutic market is expected to reach $17.98 billion in 2027 at a CAGR of 8.2%.
The pruritus therapeutic market includes revenues earned by entities by treating pruritus conditions with medicines such as aloe vera, menthol and petroleum jelly.The market value includes the value of related goods sold by the service provider or included within the service offering.
Only goods and services traded between entities or sold to end consumers are included.
Pruritus therapeutic refers to the treatment of pruritus which refer to the uncomfortable feeling that makes a person want to scratch. It can be caused by a variety of factors, which include contact with an allergen, dry skin, pregnancy, and the body’s reaction to a medicine.
North America was the largest region in the pruritus therapeutic market in 2022. The regions covered in pruritus therapeutic report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The main pruritus therapeutic types are corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressant, calcineurin inhibitors, and others.Corticosteroids refer to a kind of anti-inflammatory medication that closely matches the hormone cortisol, which the adrenal glands naturally generate.
The various disease types are atopic dermatitis or eczema, allergic contact dermatitis, urticaria, cutaneous t-cell, and others, that includes using application procedure with external use, oral, and injection. These are used by hospitals, clinics, and others.
The increasing incidences of skin disorders are significantly contributing to the growth of pruritus therapeutic.Skin conditions refer to dermatologic conditions or skin disorders such as acne, eczema, skin cancer, psoriasis, and vitiligo that affect the skin.
Pruritus therapeutics are used as a part of treatment for various skin diseases as most skin disorders have pruritus as a predominant symptom.For instance, according to World Cancer Research Fund International, a UK-based not-for-profit association related to cancer prevention, in 2020, there was 324,635 new Melanoma of skin cancer cases.
Additionally, in January 2023, according to the American Cancer Society, a US-based voluntary organization, In the United States, a projected 97,610 new melanomas cases will be diagnosed in 2023, with about 58,120 in men and 39,490 in women. Therefore, the increasing incidences of skin disorders will drive the pruritus therapeutic market.
Product innovation is the key trend gaining popularity in the pruritus therapeutic market.Major companies operating in the pruritus therapeutic market are focusing on developing innovative medications and treatments for pruritus and related conditions.
For instance, in August 2022, Maruho Co., Ltd. a Japan-based pharmaceutical company, launched the anti-IL-31 receptor, a humanized monoclonal antibody Mitchga Subcutaneous Injection 60 mg Syringes for the treatment of itching associated with atopic dermatitis. It is the first antibody drug that inhibits IL-31 signalling. IL-31 is a neuroimmune cytokine2 linked to pruritus and skin inflammation in the progression of atopic dermatitis3,4. The substance inhibits IL-31 binding to its receptor and inhibits itch and skin inflammation associated with atopic dermatitis.
In March 2023, Ipsen, a France-based biopharmaceutical company, acquired Albireo Pharma, Inc. for an undisclosed amount. The acquisition adds promising therapies for uncommon cholestatic liver disorders in children and adults, novel pipeline prospects, and technical and financial strength to Ipsen’s portfolio. Albireo Pharma, Inc. is a US-based biopharmaceutical company focused on developing and commercializing novel bile acid modulators to treat orphan pediatric liver diseases, gastrointestinal disorders, and pruritus diseases related drug development.
The countries covered in the pruritus therapeutic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The pruritus therapeutic market research report is one of a series of new reports that provides pruritus therapeutic market statistics, including pruritus therapeutic industry global market size, regional shares, competitors with a pruritus therapeutic market share, detailed pruritus therapeutic market segments, market trends and opportunities, and any further data you may need to thrive in the pruritus therapeutic industry. This pruritus therapeutic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Read the full report: https://www.reportlinker.com/p06466449/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
CONTACT: Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001